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HyperlipidemiaAMP-activated protein kinase (AMPK) is present in the arterial wall and is activated in response to cellular
stressors that raise AMP relative to ADP/ATP. Activation of AMPK in vivo lowers blood pressure but the inﬂuence
of hyperlipidemia on this response has not been studied. ApoE−/−mice on high fat diet for 6 weeks and age-
matched controlswere treatedwith theAMPK activator, AICAR daily for twoweeks. Under anesthesia, the carotid
arterywas cannulated for blood pressuremeasurements. Aortic tissuewas removed for in vitro functional exper-
iments and AMPK activity was measured in artery homogenates byWestern blotting. ApoE−/−mice had signif-
icantly raised mean arterial pressure; chronic AICAR treatment normalized this but had no effect in
normolipidemic mice, whereas acute administration of AICAR lowered mean arterial pressure in both groups.
Chronic AICAR treatment increased phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase
in normolipidemic but not ApoE−/− mice. In aortic rings, AMPK activation induced vasodilation and an
anticontractile effect, which was attenuated in ApoE−/− mice. This study demonstrates that hyperlipidemia
dysregulates the AMPK pathway in the arterial wall but this effect can be reversed by AMPK activation, possibly
through improving vessel compliance.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
AMP-activatedprotein kinase (AMPK) is an enzymewith a central role
in cellular energy homeostasis that is activated in response to a change in
the cellular balance of AMP to ADP/ATP. Often described as the cell's fuel
gauge, it becomes activated in response to cellular stressors including in-
ﬂammation, hypoxia and oxidant stress [1]. Recent evidence (reviewed in
[2]) points to a vasculoprotective role for AMPK activation that may be
mediated through inducing endothelial NO production [3,4], preventing
EC-monocyte adhesion [5] and positively regulating vascular redox bal-
ance via upregulating expression of manganese superoxide dismutase
[6], and reducing reactive oxygen species generation in response tohyper-
glycemia [7]. AMPK can also reduce the proliferative effects of stimuli such
as platelet derived growth factor and angiotensin II (Ang-II) [8], and is
likely to be intimately involved in vascular remodeling [9].
AMPK is a trimer of α (catalytic) and β and γ (regulatory) subunits
which, although ubiquitous, has tissue-speciﬁc subunit isoform expres-
sion. In vascular cells, isoforms containing the α1 subunit predominate
[10] while α2 predominates in cardiac tissue [11]. AMPK activation in-
volves phosphorylation of Thr172 on the α subunit by upstream AMPKnedy).
. This is an open access article underkinases (AMPKK), primarily LKB-1 [12] and CaMKKβ [13]. Activated
AMPK phosphorylates several downstream targets, including acetyl-
coenzyme A carboxylase (ACC) [14]. At a cellular level, this stimulates
fatty acid oxidation, mitochondrial biogenesis and glucose uptake, inhibi-
tion of fatty acid synthesis, cholesterol production and gluconeogenesis
[2]. In atherosclerosis, the presence of oxidized low density lipoproteins
increases endoplasmic reticulum (ER) stress [15] and causes a 40-fold in-
crease in expression of protein phosphatase 2A (PP2a), the enzyme re-
sponsible for inactivating AMPK [16]. Recent evidence suggests that
activation of AMPK in atherosclerosis has beneﬁcial effects including re-
versing ER stress [15] and stimulating reverse cholesterol transport from
foam cells to reduce plaque area in mice deﬁcient in apolipoprotein E
(ApoE−/−) [17,18].
Hypertension is a risk factor in development of atherosclerosis and
dysfunction of the endotheliummaybe a feature common to both pathol-
ogies [19]. The ApoE−/−mouse develops spontaneous hypercholesterol-
emia and atherosclerosis with the ﬁrst signs of disease occurring at 6 to
8weeks with features accelerated by high fat feeding [20,21]. Some stud-
ies [22] have measured an increased blood pressure in ApoE−/− mice
while others suggest no difference from control, non-atherosclerotic
mice [23,24]. Previous studies have shown that acute administration of
the AMPK activating agent, 5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside (AICAR) reduces mean arterial blood pressure (MAP)the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tensive rats dosedwith AICAR showed an acute drop inMAP thatwas not
seen in controlWKY rats, suggesting that AMPKcouldplay a role in reduc-
ing hypertension [27]. Long-term administration of AICAR or resveratrol,
another activator of AMPK, also reduced blood pressure in obese Zucker
rats [28,29] and Ang-II-induced hypertensive mice [30]. In vitro experi-
ments using aortae from mice lacking AMPKα1 indicate that AMPK may
improve endothelial function via endothelial nitric oxide synthase
(eNOS) phosphorylation [31], while chronic activation of AMPK in mice
reversed the deleterious effects of the vasoconstrictor 20-HETE on eNOS
[32]. Collectively, these studies suggest that activation of AMPK may re-
duce blood pressure though an effect on vascular eNOS. However, what
is not clear is how hyperlipidemia or established ﬁbrofatty plaques affect
AMPK activity within the arterial tree and if this attenuates the ability of
AMPK activation to modulate blood pressure. Consequently, the aims of
this study were to assess the effect of high fat feeding on MAP in
ApoE−/− mice and whether chronic activation of AMPK in vivo affects
blood pressure and vascular AMPK activity. A further aim was to study
how the presence of atherosclerotic lesions affects the hypotensive re-
sponse to acute AMPK activation and the vasodilator response to AMPK
activating agents in vitro.
2. Methods
2.1. Animal models
All in vivo experiments were performed in accordance with the
United Kingdom Animals (Scientiﬁc Procedure) Act of 1986. Mice
were housed at the University of Glasgow and maintained on 12 hour
cycles of light and dark and at ambient temperature. Two strains of
mice were used: ApoE−/− (bred in-house) and the genetic background
control (C57BL/6, Harlan). In all experiments, age-matched male mice
were used. C57BL/6 mice were fed a standard chow diet while
ApoE−/−mice commenced a high fat diet (21% lard and 0.15% choles-
terol, SDS) at 8 weeks of age. High fat diet was continued for either six
weeks to induce hyperlipidemia without arterial lesions or for 12
weeks, a time point at which we have previously demonstrated that
atherosclerotic lesions are present in the arterial tree [33]. At the end
of the experimental protocol, mice were used to study the effects of
acute or chronic AMPK activation on blood pressure and vascular func-
tion as outlined below. For some of the vascular function experiments,
mice deﬁcient in the main vascular isoform of AMPK, α1 (AMPKα−/−)
and their wild-type littermates (S129 strain) were used. These were
originally obtained from Professor Benoit Viollet (Institut Cochin,
Paris, France), bred in-house and age-matched to the 12 week fat-fed
ApoE−/−mice.
2.2. In vivo hemodynamic measurements
To study the effect of chronic AMPK activation on blood pressure and
the effect of hyperlipidemia, ApoE−/−mice (on diet for 4 weeks) were
administered daily i.p. injections of the AMPK activating agent, AICAR
(Toronto Research Chemicals Inc.) or an equivalent volume of vehicle
(distilled water) at a dose of 400 mg/kg [34,35]. An age-matched
group of C57BL/6 mice was also treated concurrently with either
AICAR or vehicle. Weight was monitored throughout to allow AICAR
dose adjustment if required. For all groups, treatment continued for
14 days at which time hemodynamic measurements were performed
under terminal anesthesia. At the end of the procedure, blood was re-
moved by cardiac puncture into EDTA-containing Vacutainers for
measurement of plasma myeloperoxidase (MPO), spleen, heart and
liver were also removed and weighed. The carotid artery and aorta
were dissected out, cleaned of surrounding fat and connective tissue
and snap-frozen in liquid nitrogen for later analysis. To study the effect
of acute AICAR administration on blood pressure in C57BL/6 mice
and ApoE−/− mice with established atherosclerosis following12 weeks of high fat diet, mice were injected with a single dose of
AICAR (400 mg/kg i.p.) or vehicle 45 min before induction of terminal
anesthesia and recording of blood pressure.
Mice were anesthetized using an isoﬂurane mixture and a polyure-
thane cannula (Harvard Apparatus) ﬁlled with heparinized saline
was inserted into the carotid artery. The cannula was connected to an
Elcomatic E751Apressure transducer andMP35data acquisition system
(BIOPAC Systems Inc.). The recordings were made using commercially
available software and data was acquired for at least 10 min in each
animal. MAP was derived from analysis of at least 5 points within the
10 minute analysis period.
2.3. Western blotting
Aortae were pulverized in liquid nitrogen and re-suspended in ice-
cold cell lysis buffer (50 mM Tris pH 7.4, 50 mM NaF, 1 mM Na4PPi,
1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 1 mM DTT and 1% cocktail
of protease inhibitors). All the samples (10 μg) were run on NuPAGE
Novex 4–12% Bis-Trismini gels (Life Technologies), transferred to nitro-
cellulose membrane and analyzed with the following primary antibod-
ies: AMPKα (1:1000; Cell Signaling Technology), phospho-AMPKα
(1:1000; Cell Signaling Technology), ACC (1:1000; Cell Signaling Tech-
nology), phospho-ACC (1:1000; Cell Signaling Technology), GAPDH
(1:40000; Abcam), and α tubulin (1:5000; Abcam). Protein bands
were visualized using an enhanced chemiluminescence detection kit
(Thermo Scientiﬁc) and the density was quantiﬁed using a GS-800™
Calibrated Densitometer (BioRad) and Quantity One BioRad software.
2.4. Measurement of MPO and plasma lipids
The MPO content of plasma from C57BL/6 and ApoE−/− mice was
analyzed using a mouse MPO ELISA kit (Hycult® Biotech Inc.). Plasma
samples were diluted 1 in 16 in dilution buffer and the assay was per-
formed as per the manufacturer's instructions. Absorbance was mea-
sured spectrophotometrically at 450 nm using a SpectraMax M2
microplate reader. Plasma total cholesterol, HDL cholesterol and triglyc-
erides were measured in undiluted plasma on an ILAB 600 clinical
chemistry analyzer, using Roche kits for HDL cholesterol. Triglyceride
and cholesterol kits were fromRandox Laboratories. All valueswere cal-
ibrated using the assigned kit calibrators and checked against the rele-
vant quality controls.
2.5. Small vessel wire myography
To assess the effects of AMPK activation on vascular tone in athero-
sclerotic mice andmice treated with AICAR, mouse aorta was removed,
cleaned of all fat and connective tissue and cut into 2 mm rings. Inmost
experiments the endotheliumwas removed by gently rubbing the inte-
rior of the vessel with a human hair and removal conﬁrmed by lack of
(b10%) vasodilator response to 10−6 M acetylcholine. Artery rings
were mounted on two stainless steel wires in a four channel wire myo-
graph (Danish Myo Technology), set to an optimum tension of 9.8 mN
[36] and allowed to equilibrate for at least 30 min before use. Vessels
were bathed in Krebs–Henseleit buffer (118 mM NaCl, 4.7 mM KCl,
1.2 mM MgSO4, 25 mM NaHCO3, 1.03 mM KH2PO4, 11 mM glucose
and 2.5 mM CaCl2) at 37 °C and gassed continuously with 95% O2
and 5% CO2. Vessel viability was checked with 40 mM KCl and
preconstriction was produced by addition of a submaximal concentra-
tion (3 × 10−8 M) of the thromboxane A2mimetic, U46619. Cumulative
concentration–response curves to AICAR (10−4 M–10−2 M) or AMPK
activator A769662 (10−6 M–5 × 10−4 M) were performed with addi-
tion of drug at 10 minute intervals. For all experiments, data were
expressed as a percentage of relaxation of the U46619-induced tone.
We alsomeasured the effect of preincubation of AMPK activating agents
on the constrictor response to U46619. In this case, 2 mM AICAR or
30 μM A769662 was added 45 min prior to U46619 contraction.
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All results are presented as mean ± SEM where n represents the
number of mice used for each experiment. In vivo data were analyzed
using a two-way ANOVA followed by Bonferroni's post hoc test.
Myography data were analyzed using two-way ANOVA to compare
the complete concentration–response curve. Biochemical data and plas-
ma lipidswere compared by one-wayANOVA formultiple comparisons.
In all cases a p value of b0.05 was taken to indicate statistical
signiﬁcance.3. Results
3.1. Blood pressure and heart rate
In the chronic AICAR experimental groups, the ApoE−/−mice were
fed high fat diet for 4 weeks before commencing either vehicle or
AICAR daily for two weeks (a total duration of 6 weeks of high fat feed-
ing). This resulted in an increased body weight compared to age-
matched C57BL/6 mice (25.0 ± 0.45 g vs. 28.0 ± 0.6 g; p b 0.001; n =
9–10). C57BL/6mice gainedweight during twoweek treatmentwith ei-
ther vehicle or AICAR. In contrast both groups of ApoE−/− mice lost
weight with a signiﬁcantly greater percentage weight loss relative to
starting weight in the AICAR treatment group (Fig. 1A). Organ weights
were also measured following 2 weeks of AICAR administration. Heart
weight did not differ between strains or with AICAR administration.
Liver weight was reduced in ApoE−/− mice compared to C57BL/6
mice and administration of AICAR increased liverweights in both strains
of mice compared to saline-treated controls (Table 1.). There was also a
marked increase in spleen weight in both ApoE−/− groups that was un-
affected by AICAR treatment (Fig. 1B). The group of ApoE−/− miceFig. 1. Body and organ weight ﬂuctuations in experimental mice. (A) The weight of each
mouse was recorded at the beginning, midpoint (day 7) and at the end of the procedure
and from these the percentage change was calculated. *p b 0.05; n = 9–10. (B) Spleen
weights were calculated as a percentage of the ﬁnal body weight of the mice. **p b 0.01,
***p b 0.001; n = 9–10.which were maintained on high fat diet for 12 weeks to study acute ef-
fects of AICAR on blood pressure also had a signiﬁcantly increased body
weight compared to age-matched C57BL/6 mice (26.75 ± 0.66 g vs.
30.23 ± 0.88 g; p b 0.01; n = 9), which was accompanied by an en-
larged spleen but no difference in heart weight (Table 1).
In ApoE−/−mice on high fat diet for 6 weeks, MAPwas signiﬁcantly
increased compared to age-matched controls. Two weeks of chronic
AICAR treatment had no effect on MAP in control mice but signiﬁcantly
lowered the value in ApoE−/−mice (Fig. 2A). Similar effects on diastolic
pressure were seen in ApoE−/− mice (Table 1) while systolic values,
which were signiﬁcantly elevated in ApoE−/−mice, were not lowered
by AICAR administration. Heart rate was also increased in vehicle-
treated ApoE−/−mice compared to C57BL/6 controls (Table 1). AICAR
administration had no effect on heart rate in either strain of mouse.
ApoE−/−mice fed the high fat diet for 12 weeks also had a signiﬁcantly
raised MAP, DAP, SAP and HR values, which were reduced in mice
injected with AICAR 45 prior to blood pressure measurement
(Table 2). However, in contrast to chronic administration of AICAR, a
single, acute administration of AICAR also signiﬁcantly reduced MAP
in the control mice (Fig. 2B and Table 2).
3.2. Expression of AMPK and ACC
The expression of phosphorylated and total AMPK and its down-
stream target, ACC, were investigated in both mouse aortae and liver
to assess the inﬂuence of hyperlipidemia and chronic AMPK activation
with AICAR on this pathway. These mice had therefore received a total
of 6 weeks of high fat diet and 2 weeks of AICAR or vehicle treatment.
Chronic treatment of control mice with AICAR did not result in any
signiﬁcant increase in the expression of total AMPK in the aorta; howev-
er, the expression of phosphorylated AMPK did increase (Fig. 3A and B).
In ApoE−/−mice, there was a reduction in both total AMPK and phos-
phorylated AMPK expression compared to C57BL/6 mice and chronic
AICAR treatment did not increase the phosphorylation of AMPK in
these mice. Consequently, the ratio of phosphorylated to total AMPK
was signiﬁcantly increased in control mice treated with AICAR, while
no effect was seen in ApoE−/−mice (Fig. 3D).
In control mice, total ACC expression in the aorta was signiﬁcantly
increased by chronic AICAR treatment and an increase in phosphorylat-
ed ACC was also observed (Fig. 4). In vehicle-treated ApoE−/− mice,
total ACC expression in the aorta was signiﬁcantly lower compared to
control mice but AICAR treatment raised the expression of both total
and phosphorylated ACC expression (Fig. 4). Consequently, the ratio of
phosphorylated to total ACC in the aorta did not change in control or
ApoE−/−mice as a result of AICAR treatment. However, this ratio was
signiﬁcantly lower in C57BL/6 mice compared to ApoE−/−mice (Fig. 4).
In homogenized samples of liver from vehicle-treated animals, total
AMPK expression was signiﬁcantly reduced in the ApoE−/− mouse
(Table 3). Chronic AICAR treatment had no effect on total AMPK expres-
sion in either strain and did not increase AMPK phosphorylation in ei-
ther strain. The ratio of phosphorylated to total AMPK was higher in
ApoE−/− mice and was found to be signiﬁcantly reduced by chronic
AICAR treatment (Table 3). There was no signiﬁcant difference in total
ACC expression in C57BL/6 and ApoE−/− liver homogenates after vehi-
cle treatment. Chronic AICAR administration had no effect on total ACC
in C57BL/6 mice but signiﬁcantly increased it in ApoE−/− mice. Phos-
phorylated ACC levels in the liver were signiﬁcantly lower in ApoE−/−
compared to C57BL/6 mice but chronic AICAR treatment had no effect
on phosphorylated ACC in either strain. The ratio of phosphorylated to
total ACC in liver was not signiﬁcantly different between strains and
AICAR had no effect in either strain (Table 3).
3.3. Plasma MPO and lipids
The inﬂuence of chronic AICAR treatment on the MPO content of
plasma from control mice and ApoE−/− mice fed on high fat diet for
Table 1
Weight and hemodynamic measurements of C57BL/6 and ApoE−/−mice after 14 days of AICAR administration.
C57BL/6 mice (6 weeks age matched) ApoE −/−mice (6 weeks high fat diet)
Vehicle AICAR Vehicle AICAR
Start weight (g) 25.0 ± 0.5 21.7 ± 0.4⁎⁎⁎ 28.0 ± 0.6⁎⁎⁎ 26.5 ± 0.6‡‡‡
Final weight (g) 26.1 ± 0.3 22.9 ± 0.4⁎⁎⁎ 26.9 ± 0.6 25.3 ± 0.5†,‡‡
Heart weight (%) 0.54 ± 0.02 0.50 ± 0.01 0.51 ± 0.02 0.47 ± 0.01
Liver weight (%) 4.91 ± 0.13 5.55 ± 0.18⁎⁎ 4.42 ± 0.16⁎ 5.24 ± 0.10†††
Spleen weight (%) 0.29 ± 0.01 0.27 ± 0.01 0.38 ± 0.03⁎⁎ 0.38 ± 0.02‡‡‡
MAP (mm Hg) 94.1 ± 1.5 96.8 ± 1.2 112.2 ± 1.5⁎⁎⁎ 98.5 ± 1.8
DAP (mm Hg) 86.8 ± 1.8 88.5 ± 1.0 110.0 ± 1.7⁎⁎⁎ 88.4 ± 1.8
SAP (mm Hg) 105.1 ± 1.3 110.3 ± 2.2 115.3 ± 1.6⁎⁎⁎ 112.8 ± 2.2
PP (mm Hg) 18.3 ± 0.9 21.8 ± 2.6 5.3 ± 0.5⁎⁎⁎ 24.4 ± 1.5†††
HR (bpm) 317.7 ± 13.9 344.7 ± 20.2 410.7 ± 15.1⁎⁎ 381.9 ± 15.1
Startweight refers toweight on commencing vehicle or AICAR treatment. Organweightwas taken as a percentage of theﬁnal bodyweight.MAP, heart rate (HR), diastolic arterial pressure
(DAP), systolic arterial pressure (SAP) and pulse pressure (PP) were calculated from the blood pressure trace. n = 6–10.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001 vs. C57BL/6 vehicle.
† p b 0.05.
††† p b 0.001 vs. ApoE−/− vehicle.
‡‡ p b 0.01.
‡‡‡ p b 0.001 vs. C57BL/6 AICAR.
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matic increase inMPO levels compared to vehicle-treated C57BL/6mice
(151.9± 17.9 ng/ml vs. 598.2± 55.0 ng/ml; p b 0.001; n=8–9). AICAR
treatment had no effect on MPO levels in control mice but signiﬁcantly
increased MPO in the plasma of ApoE−/−mice (598.2 ± 55.0 ng/ml vs.
762.7 ± 71.12 ng/ml; p b 0.05; n = 9). Compared to age-matched
C57BL/6 mice, ApoE−/− mice on high fat diet for 6 weeks had
signiﬁcantly raised total cholesterol (15.52 ± 0.75 mg/dl vs. 1.99 ±C57BL/6 ApoE -/-
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Fig. 2.Mean arterial pressure (MAP) of C57BL/6 and ApoE−/−mice treated chronically or
acutely with AICAR. MAPwasmeasured by cannulation of the left common carotid artery.
(A) ApoE−/− mice were fed high fat diet for a total of 6 weeks with vehicle or AICAR
injected daily for the ﬁnal 2 weeks. C57BL/6 mice received chow diet and either vehicle
or AICAR. **p b 0.01, ***p b 0.001; n = 6–10. (B) MAP of ApoE−/−mice on high fat diet
for 12 weeks and age-matched C57BL/6 controls administrated vehicle or AICAR 45 min
before blood pressure measurement. **p b 0.01; n = 6–10.0.11 mg/dl; p b 0.05, n = 9–10) and triglycerides (0.91 ± 0.16 mg/dl
vs. 0.32 ± 0.04 mg/dl; p b 0.05, n = 9–10) while HDL-cholesterol was
not raised (2.15±0.12mg/dl vs. 1.80±0.10mg/dl; n=9–10). Chronic
treatment with AICAR had no effect on the lipid proﬁle in C57BL/6 mice
(data not shown) but signiﬁcantly raised HDL-cholesterol (2.15 ±
0.12 mg/dl vs. 3.62 ± 0.26 mg/dl; p b 0.05, n = 9–10) and total choles-
terol (15.52± 0.75mg/dl vs. 19.43±0.99mg/dl; p b 0.05, n=9–10) in
the ApoE−/− mouse without any effect on triglycerides (0.91 ±
0.16 mg/dl vs. 0.98 ± 0.11 mg/dl; n = 9–10).3.4. Vascular function in vitro
In these experiments, aortae from12week fat-fedmicewere used as
we have shown previously that the arteries contain fatty lesions [33]. In
denuded aortic rings, both AMPK activating agents AICAR and A769662
produced a relaxation which was signiﬁcantly reduced in 12 week fat-
fed ApoE−/− mice (Fig. 5A and B). In endothelium-intact rings from
C57BL/6 mice, relaxation of a similar magnitude to denuded rings
(Fig. 5C and D) was observed. In 12 week fat-fed ApoE−/− mice, the
presence of intact endothelium (deﬁned as a 50% relaxation in response
to acetylcholine) could not be conﬁrmed (n = 7).Table 2
Weight and hemodynamic measurements after acute AICAR administration in C57BL/6
and 12 week fat-fed ApoE−/−mice.
C57BL/6 mice (12 weeks age
matched)
ApoE −/−mice (12 weeks high
fat diet)
Vehicle AICAR Vehicle AICAR
Body weight (g) 26.7 ± 0.7 30.2 ± 0.8⁎⁎
Heart weight (%) 0.69 ± 0.04 0.67 ± 0.06
Liver weight (%) 5.42 ± 0.11 4.09 ± 0.2⁎⁎⁎
Spleen weight (%) 0.27 ± 0.02 0.55 ± 0.07⁎⁎
MAP (mm Hg) 94.3 ± 1.6 83.2 ± 1.8⁎ 112.3 ± 3.5⁎⁎⁎ 102.3 ± 2.9††
DAP (mm Hg) 79.2 ± 2.3 64.1 ± 1.9⁎⁎ 107.4 ± 2.1⁎⁎⁎ 98.0 ± 1.1†
SAP (mm Hg) 109.5 ± 2.5 103.9 ± 3.09 117.8 ± 2.3⁎ 106.3 ± 3.7†
PP (mm Hg) 31.0 ± 0.8 39.6 ± 2.2 10.4 ± 3.0 8.3 ± 2.6
HR (bpm) 440.1 ± 7.5 400.4 ± 21.2⁎ 486.7 ± 16.7⁎ 350.1 ± 30†
Organ weight was taken as a percentage of the body weight. MAP, HR, DAP, SAP and PP
were calculated from the blood pressure trace. n = 6–10.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001 vs. C57BL/6 vehicle.
† p b 0.05.
†† p b 0.01 vs. ApoE−/− vehicle.
Fig. 3. AMPKα expression in aortae of C57BL/6 and ApoE−/−mice treated with AICAR. (A) Blots shown are representative. (B) Phosphorylated and (C) total AMPKα were divided by
GAPDH to adjust for protein loading to measure the amount of each form of the enzyme. (D) A ratio of phosphorylated to total AMPKαwas calculated to measure the phosphorylation
status of the enzyme. *p b 0.05, **p b 0.01, ***p b 0.001; n = 4.
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tested the effect of a single addition of either AICAR (2 mM) or
A769662 (30 μM) prior to contracting the ring with U46619. Both
agents produced a signiﬁcant anticontractile effect but this was signiﬁ-
cantly reduced with AICAR in the ApoE−/− aorta (Fig. 6). To investigate
this further we repeated the experiments using AMPKα1−/− or wild-
type littermates (S129). In the KO animals, the anticontractile effect ofboth AICAR and A769662was lost, conﬁrming that it is due to activation
of AMPK (Fig. 6).
4. Discussion
In this study we demonstrate for ﬁrst time that chronic activation of
AMPK can normalize the raised MAP in hyperlipidemic ApoE−/−mice.
Fig. 4. ACC expression in aortae of C57BL/6 and ApoE−/−mice treated with AICAR. (A) Blots shown are representative. (B) Phosphorylated and (C) total ACC were divided by GAPDH to
adjust for protein loading to measure the amount of each form of the enzyme. (D) A ratio of phosphorylated to total ACC was calculated to measure the phosphorylation status of the en-
zyme. *p b 0.05, **p b 0.01; n = 4.
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increased by chronic AMPK activation, so we speculated that the
ApoE−/− mouse has reduced vascular compliance that underlies the
raised MAP. In support of this, ApoE−/− mice fed a high fat diet for 3
months, a time point at which atherosclerotic lesions are evident [33],
had a reduced vasodilator response to AMPK activating agents andwere more sensitive to contractile agents. Since ApoE−/− mice also
had reductions in the amount of phosphorylated and total AMPKα
and ACC following AICAR treatment, we conclude that the AMPK path-
way is dysregulated in the artery wall of hyperlipidemic mice and this
may acceleratemay of the processeswhich contribute to atherosclerotic
lesion formation.
Table 3
Expression of AMPK and ACC in homogenized liver samples from C57BL/6 and ApoE−/−mice after 14 days of AICAR administration.
C57BL/6 mice ApoE −/−mice
Vehicle AICAR Vehicle AICAR
Phospho AMPK 0.54 ± 0.05 0.46 ± 0.03 0.70 ± 0.07 0.58 ± 0.09
Total AMPK 1.01 ± 0.09 0.94 ± 0.14 0.42 ± 0.02⁎⁎ 0.46 ± 0.02‡‡
Phosphorylated/total AMPK 0.53 ± 0.02 0.51 ± 0.07 1.68 ± 0.18⁎⁎⁎ 1.28 ± 0.05†,‡‡‡
Phospho ACC 2.07 ± 0.18 1.84 ± 0.27 1.31 ± 0.07⁎ 1.24 ± 0.23
Total ACC 1.58 ± 0.18 1.79 ± 0.27 0.98 ± 0.06 1.03 ± 0.15‡
Phosphorylated/total ACC 1.34 ± 0.13 1.03 ± 0.08 1.34 ± 0.07 1.20 ± 0.06
Values for total ACC and phosphorylated ACC are given as a ratio of the density of the band corresponding to the protein of interest relative to the density of the GADPH band. A ratio of
phosphorylated to total ACC was used to assess activation of the enzyme. n = 4.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001 vs. C57BL/6 vehicle.
† p b 0.05 vs. ApoE−/− vehicle.
‡‡ p b 0.01.
‡‡‡ p b 0.001 vs. C57BL/6 AICAR.
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ApoE−/− mice at a time point where atherosclerotic lesions are not
established, since there is little information on blood pressure and vas-
cular function early in the disease process. Mean arterial, diastolic and
systolic pressures as well as heart rate were all elevated while pulse
pressure was reduced in ApoE−/− mice fed on the high fat diet for
6 weeks compared to C57BL/6 controls. Some previous studies [37] re-
ported no differences in hemodynamic measurements between age-
matched 6 week old ApoE−/− and C57BL/6 mice, but these mice were
not fed on a high fat diet, which would be expected to accelerate path-
ological changes in vessel structure and function. However, other stud-
ies in young ApoE−/−mice have shown elevated systolic and diastolic
pressures and heart rates compared to C57BL/6 control mice [22], and
a decrease in arterial elasticity caused by excessive extracellular matrix
deposition may be responsible [38]. ApoE−/−mice maintained on the
same diet for 3 months had a similarly raised MAP compared to age-
matched C57BL/6 mice, indicating that the hypertension is established
early after fat feeding in this model and does not worsen as atheroscle-
rotic lesions are established. Inﬂammatory burden was also raised even
after only 6 weeks fat feeding, with enlarged spleens [39] and raised
plasma MPO in ApoE−/−mice compared to controls.
Chronic AMPK activation by AICAR normalized MAP in ApoE−/−
mice without affecting heart rate, whereas acute administration had a
hypotensive effect in both atherosclerotic ApoE−/− mice and age-
matched C57BL/6mice. AICAR has previously been shown to have a hy-
potensive effect when given acutely to spontaneously hypertensive rats
and humans [25–27] while chronic AMPK activation lowered blood
pressure in insulin resistant rats [28,29] and in Ang-II-induced hyper-
tension [30]. The acute reduction in blood pressure may be due to in-
creased nitric oxide bioavailability from the vascular endothelium
[27]. The hypotensive response to acute AICAR in our study was the
same in C57BL/6 and ApoE−/−mice, suggesting a fully functional endo-
thelium following 12weeks of fat feeding. However, this is not support-
ed by previous reports showing very early dysfunction in this model
[40]. The hypotensive effect may be mediated by a direct effect on the
vascular smooth muscle cells which also express AMPK and indeed,
we present data showing relaxation to two AMPK activating agents in
endothelium denuded aortic rings in this study (Fig. 5).
Interestingly, chronic AICAR administration also caused signiﬁcant
weight loss in the ApoE−/−mouse only. Previous studies have reported
that hypothalamic AMPK activity is involved in modifying food intake
and activation of the AMPK pathway induces hyperphagia and weight
gain [41,42]. However, a recent study demonstrated no change in
body weight in rats chronically dosed with AICAR for up to 8 weeks
but did show increased leptin sensitivity, reduced adiposity and in-
creased oxidative capacity of white adipose tissue [43]. In control
mice, weight gain was the same in AICAR and vehicle-treated animals,
but signiﬁcant weight loss was seen in ApoE−/− mice treated withAICAR. In the study by [43], chronic dosing with AICAR induced up to
10% reduction in food intake. We did not monitor food intake in the
present study, but the normal weight gain in the C57 mice treated
with either vehicle or AICAR suggests food intake was unaffected by
AICAR. Theweight loss in theApoE−/− groupmayhave beendue to dys-
regulated AMPK signaling caused by hyperlipidemia, a feature observed
in previous studiedwith hypertensive rats [27] and insulin resistant rats
[28]. However we cannot rule out a reduction in food intake in the
ApoE−/−mice. Dysregulation of AMPK and its downstream target ACC
in hyperlipidemic mice is supported by our data on vascular expression
and phosphorylation of these proteins. Not unexpectedly, chronic
AICAR treatment upregulated the phosphorylation status of AMPK and
its downstream target ACC in the aorta of C57BL/6 mice, which is likely
to indicate an increase in activity of the enzyme. In complete contrast,
ApoE−/−mice had signiﬁcantly reduced expression of phosphorylated
and total AMPKα and ACC in response to AICAR. Vehicle-treated
ApoE−/− mice also had reduced levels of total ACC compared to
vehicle-treated C57BL/6 mice, which resulted in an elevation in the
phosphorylated to total ratio of ACC. The reduced expression and func-
tion of AMPK may be a result of the developing atherosclerosis but
would certainly render the animal less sensitive to changes in cellular
redox balance and perhaps less able to deal with metabolic distur-
bances. The reduced AMPK expression may be due to higher levels of
protein phosphatase 2A, which is partly responsible for inactivating
AMPK [16].
In the liver, there was a reduction in the total amount of AMPKα in
ApoE−/−mice and AICAR did not increase phosphorylation. Phosphory-
lated ACCwas also reduced in ApoE−/−mice. In a previous investigation,
AMPK activity was increased 3.6-fold in the liver only 1 h after adminis-
tration of AICAR [28], which suggests the rapid metabolism of AICAR by
the liver and subsequent activation of AMPK signaling. In the ApoE−/−
mouse, the reduction in total AMPK could have affected the ability of
AICAR to induce phosphorylation. The chronic nature of the AICARdosing
may also have resulted in desensitization of the target protein. A reduc-
tion in total hepatic AMPK has been shown in other disease models
such as obese Zucker rats [29]. Since AMPK activationwould increase he-
patic fatty acid oxidation and therefore the catabolism of free fatty acids
and triglycerides [44], a reduction in the activity of the enzyme or its abil-
ity to be activated by agents such as AICAR could adversely affect lipid
proﬁle and exacerbate diet-induced hyperlipidemia.
As anticipated, even after only 6weeks of high fat diet ApoE−/−mice
displayed features of generalized inﬂammation such as increased spleen
weight and raised plasma MPO, the latter being consistent with pub-
lished reports [45–47]. The plasma MPO content found in the present
study is much higher than those found previously in mice deﬁcient in
low density lipoprotein receptor fed on a high fat diet for 6 weeks
(160 ng/ml) [48] but this could be due to gender or strain differences.
In addition, AICAR treatment signiﬁcantly increased MPO in the plasma
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Fig. 5. Relaxation of C57BL/6 and ApoE−/− aortic rings to AMPK activating agents.
(A) Denuded aortic rings from 3 month high fat-fed ApoE−/− mice and age-matched
C57BL/6 controls were precontracted with U46619 and concentration–response curves
to (A) AICAR and (B) A769662 were produced using small vessel wire myography. In en-
dothelium-intact aortic rings fromC57BL/6mice, AICAR (C) andA769662 (D) also induced
a relaxation of similar magnitude to denuded rings. **p b 0.01, ***p b 0.001; n = 7.
Fig. 6. Effect of preincubation of AMPK activating agents on the constrictor response to
U46619 in mouse aortae. (A) 2 mM AICAR or 30 μM A769662 were added for 45 min
prior to U46619 contraction in 3 month fat-fed ApoE−/− mice and aged-matched
C57BL/6 mice. ***p b 0.001; †p b 0.05 vs. C57BL/6 AICAR; n = 4–9. (B) 2 mM AICAR or
30 μM A769662 were added for 45 min prior to U46619 contraction in AMPKα1−/−
mice and their wild-type littermates (S129). *p b 0.05, ***p b 0.001; n = 4–6.
100 F.H. Greig et al. / Vascular Pharmacology 74 (2015) 93–102of ApoE−/−mice but not normolipidemic control mice. This result was
unexpected as a previous study has shown AMPK activation to cause a
decrease in MPO levels, albeit in lung tissue and not in the circulation
[49]. A possible explanation is activation of AMPK in neutrophils by
AICAR leading to the release of MPO [50]. ApoE−/−mice may have in-
creased circulating neutrophils or perhaps increased neutrophil AMPK
content which could account for the lack of effect of AICAR on MPO
levels in C57BL/6 mice, though we did not measure neutrophil counts
in this study so this remains speculative.Previous reports indicate that AMPK activationmay induce vasodila-
tion via activation of eNOS and in this study we demonstrated that a
single, acute administration of AICAR lowered blood pressure in both
C57BL/6 and ApoE−/− mice. Therefore, we performed some experi-
ments in isolated mouse aortic rings from C57BL/6 and 3 month fat-
fed ApoE−/−mice to investigate how AMPK activation affects vascular
tone. We found that both AICAR and A769662 induced vasodilation
that did not require an intact endothelium. To avoid the effect of endo-
thelial dysfunction in theApoE−/− group, we studied only denuded aor-
tic rings. The vascular effects of both agents were due to AMPK
activation since they were absent in aortic rings from global
AMPKα1−/−mice (Fig. 6) and it is likely that AMPK present in the me-
dial smoothmuscle is responsible for the vasodilator effect. The blunted
response to bothAMPK activators in the ApoE−/−mouse and the reduc-
tion in the anticontractile effect in response to AMPK activation is in line
with the AMPK and ACC expression data, which showed altered expres-
sion and function following high fat diet in the ApoE−/− mouse. An
anticontractile effect in response to AMPK activation at the level of the
endothelium has been published [32] but our data showing that the
anticontractile effect in denuded vessels is attenuated in atherosclerotic
animals has not been reported previously.
Here we demonstrate that the elevated blood pressure in 6-week
fat-fed ApoE−/−mice can be normalized without any change in heart
rate by chronic activation of AMPK. The beneﬁcial effect of chronic acti-
vation may be due to improvements in arterial compliance. The
ApoE−/−mice also had dysregulated AMPK expression and phosphory-
lation in the arterywall, whichmay contribute to disease progression. In
ApoE−/−mice with established ﬁbrofatty plaques, AICAR could still in-
duce a hypotensive response when administered acutely, suggesting
that even although the AMPK pathway is dysregulated, sufﬁcient activ-
ity remains to dilate blood vessels. In vitro experiments with denuded
101F.H. Greig et al. / Vascular Pharmacology 74 (2015) 93–102aortic rings showed that AMPK activity in the vascular smooth muscle
has anticontractile and vasodilator activity which could maintain the
hypotensive response in the ApoE−/−mousewhen endothelial function
is compromised. Based on our ﬁndings, the role of AMPK inmaintaining
vascular health and blood pressure deserves further investigation, to-
gether with the therapeutic effects of AMPK activators.Acknowledgments
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